Once heralded as its next big cash cow, Jazz takes a marked down price for not-so-hot sleep disorder drug

Once upon a market time, the analysts at Cowen gave Jazz Pharmaceuticals a ringing endorsement of their follow-up sleep disorder drug Sunosi, confident it could ring up annual sales of $500 million-plus. That was about 4 years ago.